CN1268381C - Leukopenia treating Chinese traditional medicine - Google Patents
Leukopenia treating Chinese traditional medicine Download PDFInfo
- Publication number
- CN1268381C CN1268381C CN 200310110575 CN200310110575A CN1268381C CN 1268381 C CN1268381 C CN 1268381C CN 200310110575 CN200310110575 CN 200310110575 CN 200310110575 A CN200310110575 A CN 200310110575A CN 1268381 C CN1268381 C CN 1268381C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- leukopenia
- treatment
- lactose
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a traditional Chinese medicine for treating leukopenia, which is prepared from astragalus root, suberect spatholobus stem, hairyvein agrimonia herb and bud, tangerine peel, lucid ganoderma, processed pinellia tuber, bamboo shavings, pyrrosia leaf, hawthorn fruit, Chinese date, beta-CD inclusion compound, pregelatine starch and lactose to be made into granules.
Description
The invention relates to that a kind of treatment is put, the invention of chemotherapy leukopenia Chinese medicine, be specifically related to a kind of with Chinese medicine being used for the treatment of of making put, the Chinese medicine of leukopenia due to the chemotherapy, belong to the field of Chinese medicines.
Malignant tumor is one of three human at present big lethal factors, and radiation and chemotherapy is the common method of western medical treatment malignant tumor, and Chang Yinwei lacks the medicine of the antagonism caused by radiotherapy and chemotherapy bone marrow inhibition of satisfactory effect, causes the chemicotherapy scheme to be difficult to the garden and completely finishes.Therefore for this treatment of diseases of tumor, need the medicine of antagonism caused by radiotherapy and chemotherapy bone marrow inhibition.Seem a lot of though can be applied to the leukopenic medicine of caused by radiotherapy and chemotherapy in clinical, but the oral formulations of Western medicine all lacks certainly and persistent curative effect (" contemporary combination of Chinese and Western medicine haematol "), though and Hui Er blood curative effect is affirmed cost an arm and a leg (500～800 yuan every).In the Chinese patent medicine, all from the legislation of enriching blood of spleen reinforcing the kidney invigorating, QI invigorating, emphasis has been considered all only to be suitable for the bone marrow depression that caused by chemicotherapy simple deficiency syndrome, and to be unfavorable for the stomach-QI being unable to descend normally person that holds concurrently.Therefore need a kind of bone marrow inhibition, raising peripheral blood leucocyte counting that can either resist chemicotherapy in clinical, can resist the medicine of chemicotherapy gastrointestinal reaction again.Most patients of cancer need cooperate the chemicotherapy treatment, and need carry out two to four chemicotherapy treatments for each person every year, and the person reaches more than half and the leukopenia occurs in chemicotherapy.Therefore resisting the caused by radiotherapy and chemotherapy leukopenia has vast market prospect.At this situation inventor this granule for oral administration.
The purpose of this invention is to provide a kind of Chinese medicine that can treat the chemicotherapy leukopenia.
Medicine of the present invention is to be prepared from following Chinese drug-treated group part, and each component is a weight portion:
Radix Astragali 660-700 part
Caulis Spatholobi 660-700 part
Herba Agrimoniae 660-700 part
Pericarpium Citri Reticulatae 220-250 part
Ganoderma 660-700 part
Rhizoma Pinelliae Preparatum 220-250 part
Caulis Bambusae In Taenia 220-250 part
Folium Pyrrosiae 660-700 part
Fructus Crataegi 220-250 part
Fructus Jujubae 220-250 part
The preferred weight proportioning of above-mentioned each component is:
The Radix Astragali 660
Caulis Spatholobi 660
Herba Agrimoniae 660
Pericarpium Citri Reticulatae 220
Ganoderma 660
Rhizoma Pinelliae Preparata 220
Caulis Bambusae In Taenia 220
Folium Pyrrosiae 660
Fructus Crataegi 220
Fructus Jujubae 220
In each component, also add beta-CD inclusion, pregelatinized Starch, lactose, contain beta-CD inclusion 5g, pregelatinized Starch 220g, lactose 110g in every 1000g granule.
Medicine of the present invention has benefiting QI and nourishing blood, the effect of regulating the stomach and sending down the abnormal ascending QI.To put, leukopenia due to the chemotherapy, see that the QI and blood deficiency stomach-QI being unable to descend normally disease of holding concurrently causes spiritlessness and weakness, the few lazy speech of gas, lusterless complexion, feel sick nausea, pale tongue person determined curative effect.
Following clinical observation report data further illustrates the curative effect of medicine of the present invention.
1. physical data:
This group is observed 37 examples altogether, male's 21 examples wherein, women's 16 examples; 18～65 years old age, average 50.32 ± 11.463 years old; Protopathy is pulmonary carcinoma 10 examples, nasopharyngeal carcinoma 6 examples, cervical cancer 4 examples, gastric cancer 3 examples, breast carcinoma 3 examples, hepatocarcinoma 2 examples, intestinal cancer hepatic metastases 2 examples, sick 2 examples of Fei Hejiejinshi, other tumor 5 examples; Leukopenia person 19 examples after the chemotherapy, leukopenia person 16 examples after the radiotherapy, chemotherapy combination with radiotherapeutic person 2 examples; Double stomach-QI being unable to descend normally person 32 examples.
2. study subject is selected
2.1 the diagnostic criteria of leukopenia: " clinical disease diagnosis is according to curing the improvement standard " that reference in June, 1998 People's Medical Officer Press publishes: become the continuous review of human peripheral leucocytes sum all to be lower than 4.0 * 10 2 times
9/ L.
The stomach-QI being unable to descend normally diagnostic criteria 2.2 deficiency of both QI and blood is held concurrently:
(1) deficiency of both QI and blood diagnostic criteria: " the dialectical reference standard of Chinese medicine deficiency-syndrome " that national combination of Chinese and Western medicine deficiency syndrome of reference and senile disease research Professional Committee revised in May, 1986: possess syndrome of deficiency of QI and syndrome of deficiency of blood diagnostic criteria simultaneously.
Syndrome of deficiency of QI: 1. spiritlessness and weakness; 2. weak breath or lazyness are sayed; 3. spontaneous perspiration; 4. enlarged tongue or tooth seal is arranged; 5. deficient pulse unable (weak, soft, moisten etc.).Possess three.
Syndrome of deficiency of blood: 1. pale complexion; 2. rise dim immediately at the moment; 3. lip pale tongue; 4. thready pulse.Possess three.
(2) stomach-QI being unable to descend normally diagnostic criteria: with reference to national standard " tcm clinical practice diagnosis and treatment term ": 1. anorexia; 2. feel sick; 3. vomiting.Possesses one.
2.3 standard of including in: possess following three simultaneously.
1. because of suffering from all kinds of malignant tumor blood system malignant tumor such as (except) leukemia, carry out radiotherapy or chemotherapy, treatment is ended or is finished the course of treatment in back 3 days; 2. meet leukopenia diagnostic criteria person; 3. meet the deficiency of both QI and blood diagnostic criteria, or double stomach-QI being unable to descend normally person.
2.4 exclusion standard:
1. radiotherapy, chemotherapeutic period, or total white blood cells is lower than 2.0 * 10
9/ L, neutrophilic granulocyte is lower than 0.5 * 10
9/ L even scarce as the person; 2. the age is less than 18 years old, greater than 65 years old; 3. can not take medicine on request, maybe can not finish person's course of treatment; 4. concurrent severe infections person; 5. the tumor rapid deterioration is difficult to accept this therapist; 6. merge severe cardiac, brain, kidney, lung primary disease, the psychotic; 7. primary leukopenia is by leukopenia due to the diseases such as leukemia, aplastic anemia; 8. leukopenia due to the other drug except that radiotherapy, chemotherapy factor; 9. to this medicine allergy sufferers.
3. observational technique:
3.1 observe routine number: 37 examples.
3.2 grouping and contrast: own control before and after the single group treatment of employing.
3.3 the medication and the course of treatment: rise white granule, produced by Guohua Pharmacy Co., Ltd., Hunan, the Hunan Inst of Traditional Chinese Medicine changes the research department for clinical dose to be provided, and lot number is 990204.Instructions about how to take medicine: each 1 bag, every day 3 times, 15 days is a course of treatment, finishes the course of treatment to continue to observe for 2 weeks after the drug withdrawal.
3.4 observation index:
1. the deficiency of both QI and blood stomach-QI being unable to descend normally primary symptom of holding concurrently adopts classification point system (as follows), observes 1 time in per 3 days during the medication, observes weekly between withdrawal time 1 time;
2. routine blood test comprises hemoglobin, numeration of leukocyte and classification, platelet count, checks 1 time before the treatment, checks 1 time in per 5 days during the medication, checks weekly between withdrawal time 1 time.
3. routine urinalysis, stool routine, electrocardiogram, liver function (serum transaminase), renal function (blood urea nitrogen, creatinine), immune indexes is respectively checked 1 time before and after observing.
4. result of the test:
4.1 efficacy assessment standard:
(1) the deficiency of both QI and blood stomach-QI being unable to descend normally person efficacy assessment standard of holding concurrently:
1. the deficiency of both QI and blood stomach-QI being unable to descend normally point system of holding concurrently:
Spiritlessness and weakness: 0 minute: do not have; 2 minutes: light, but do not influence daily life and work; 4 minutes: heavier, influence daily life and work more, but must not lie up; 6 minutes: heavy, must lie up, can't take care of oneself.
Deficiency of QI with disinclination to talk: 0 minute: do not have; 2 minutes: light, activity aftersensation gas was not enough, not initiatively with people's talk; 4 minutes: heavier, it was not enough often to feel gas, did not like the talk with the people; 6 minutes: heavy, it was not enough to feel gas constantly, and normal silence even other people initiatively talk with it, is also seldom answered.
Spontaneous perspiration: 0 minute: do not have; 2 minutes: light, idol had; 4 minutes: heavier, often have, but during You Youzhi; 6 minutes: weigh, constantly continuous perspiration.
Lusterless complexion: 0 minute: do not have; 2 minutes: light, only other people examined and can find; 4 minutes: heavier, relatively can obviously distinguish with the people around; 6 minutes: heavy, white as paper, have no color.
Rise dim immediately at the moment: 0 minute: do not have; 2 minutes: light, accidental; 4 minutes: heavier, normal sending out; 6 minutes: heavy, outbreak can not be stood constantly.
Anorexia: 0 minute: appetite and diet are normal; 2 minutes: do not have appetite, but keep former appetite; 4 minutes: no appetite, appetite reduces 1/3 than before sick; 6 minutes: appetite was eaten very less or not, and appetite reduces more than 2/3.
Nausea and vomiting: 0 minute: do not have; 2 minutes: light, idol had, and can stand; 4 minutes: heavier, be impatient at, must can control by the medication object space; 6 minutes: heavy, also can not control with medicine.
Tongue, arteries and veins: picture of the tongue in the aforementioned deficiency of both QI and blood, pulse condition person occur, counted 2 fens, do not have and then do not score.
2. the deficiency of both QI and blood efficacy assessment standard of stomach-QI being unable to descend normally of holding concurrently: the score standard according to this card is scored, and calculates score value before and after the treatment again, calculates curative effect percent then:
Be almost recovered: curative effect percent 〉=91%;
Produce effects: curative effect percent 66～91%;
Effectively: curative effect percent 35～65%;
Invalid: curative effect percent≤35%.
(2) leukopenic efficacy assessment standard due to after radiotherapy, the chemotherapy: with reference to " clinical disease diagnosis is according to curing the improvement standard ".
1. cure: leukocyte＞4.0 * 10
9/ L, neutrophilic granulocyte absolute value＞1.8 * 10
9/ L, and keep more than 2 weeks.
2. produce effects: period in a medicine leukocyte＞4.0 * 10
9/ L, neutrophilic granulocyte absolute value＞1.8 * 10
9/ L, but the drug withdrawal viewing duration drops to below normal range again.
3. take a turn for the better: treatment back leukocyte raises 1.0 * 10
9More than/the L, but do not reach person's normal range.
4. invalid: treatment back leukocyte raises and does not reach above-mentioned standard, even does not have obvious rising person.
4.3 therapeutic outcome
4.3.1 the leukopenia curative effect of disease is analyzed: former observation case load is 40 examples, wherein 3 routine neutrophilic granulocyte number≤0.5 * 109/L belong to agranulocytosis, so get rid of.According to above efficacy assessment standard, cure in 37 examples: 35 examples, produce effects: 2 examples, take a turn for the better: 0 example is invalid: 0 example, cure rate 94.6%, obvious effective rate 100%, total effective rate 100%.
4.3.2 different period leukocyte return to positive common practice and count analysis: see Table 1.As seen from the table, after taking medicine 5 days, patient's leukocyte of 54.05% has returned to normal level, and after taking medicine 10 days, 64.87% patient returns to normal level, takes medicine 15 days, and then 100% patient returns to normal level.
Table 1 leukocyte returns to positive common practice number and time relation.
| Before the treatment | Treated the 5th day | The 10th day | The 15th day | Control 1 week of back | Control 2 weeks of back | |
| The positive undesired routine number of common practice number | 0 37 | 20 17 | 24 13 | 37 0 | 35 2 | 37 0 |
4.3.3 the relation of the degree of being in a bad way and curative effect: be divided into 4 degree according to leukopenic order of severity: 1. I degree: total white blood cells reduces, but＞3.0 * 109/L; 2. II degree: total white blood cells＞2.0 * 109/L; 3. III degree: total white blood cells＞1.0 * 109/L; 4. IV degree: total white blood cells＜1.0 * 109/L.In 40 examples, belong to I degree person 20 examples, II degree person 13 examples, III degree person 2 examples, IV degree person 2 examples, the curative effect between each degree relatively sees Table 2.As seen from the table, curative effect and state of an illness weight have certain relation, even but IV degree person is also all effective.
The relation of table 2 state of an illness weight and curative effect relatively.
| The example number | The I degree | The II degree | The III degree | The IV degree | |
| The basic produce effects enabledisable of curing | 37 35 2 0 0 | 20 20 0 0 0 | 13 12 1 0 0 | 2 2 0 0 0 | 2 1 1 0 0 |
The stomach-QI being unable to descend normally card therapeutic effect of syndrome analysis 4.3.4 QI and blood deficiency is held concurrently: according to the QI and blood deficiency stomach-QI being unable to descend normally card therapeutic effect of syndrome evaluation criteria of holding concurrently, substantially cure in 37 examples: 14 examples, produce effects: 6 examples, effectively: 13 examples, invalid: 4 examples, basic cure rate is 37.8%, obvious effective rate 54.1%, total effective rate 89.2%.
4.3.5 different time sections syndrome integrated value relatively: see Table 3.As seen from the table, the hold concurrently syndrome integrated value of stomach-QI being unable to descend normally card of QI and blood deficiency began to occur obvious decline on the 9th day in the back of taking medicine, difference has significance meaning (P＜0.01), and its total mark value and QI and blood deficiency and stomach-QI being unable to descend normally card integrated value descend synchronously, and difference all has significance meaning (P＜0.01).
Each time period syndrome integrated value of table 3 relatively.
| Before the treatment | Treated the 3rd day | The 9th day | Controlled in the 15th day | Control 1 week of back | Control 2 weeks of back | |
| Total mark value deficiency of both QI and blood score value stomach-QI being unable to descend normally card score value | 23.1± 12.48 16.1± 8.94 6.9± 5.14 | 20.1± 11.79 14.6± 8.35 5.5± 4.40 | 11.5±★★ 8.53 10.4±★ 11.31 2.7±★★ 3.02 | 6.7±★★ 5.72 5.24±★★ 4.30 1.5±★★ 2.13 | 5.2±★★ 5.89 3.81±★★ 4.61 1.3±★★ 1.57 | 5.0±★★ 5.88 3.7±★★ 4.54 1.3±★★ 1.83 |
Annotate: ★ and preceding relatively P＜0.05 of treatment; ★ ★ and preceding relatively P＜0.01 of treatment.
4.3.3 the influence to the leukocyte heterogeneity: see Table 4.As seen from the table, rise white granule therapy after 5 days, total white blood cells promptly has obvious rising, and neutrophilic granulocyte rises synchronously, with comparing difference before the treatment significance meaning (P＜0.01) is arranged all, and is progressively ascendant trend, to the 10th day, its average promptly returned to more than the normal level.When total white blood cells and neutrophilic granulocyte rose, lymphocyte was also in rising trend, but later when occurring, and had statistical significance (P＜0.05) treatment the 10th talent.Eosinophilic granulocyte and other leukocyte also have certain rising.
The influence of table 4 pair each composition of leukocyte.
| Before the treatment | The 5th day | The 10th day | The 15th day | Control the 1st week of back | The 2nd week | |
| Total white blood cells (* 109/L) neutrophilic granulocyte (* 109/L) | 2.89± 0.744 1.73± 0.731 | 4.08±★★ 1.327 2.59±★★ 0.899 | 4.77±★★ 1.745 3.16±★★ 1.407 | 5.75±★★ 1.207 3.94±★★ 1.310 | 5.76±★★ 1.157 3.92±★★ 1.294 | 6.38±★★ 1.232 4.49±★★ 1.375 |
| Lymphocyte number (* 109/L) acidophil (* 109/L) other leukocyte (* 109/L) | 0.87± 0.488 0.14± 0.167 0.16± 0.177 | 1.08± 0.635 0.41±★ 1.500 0.23± 0.216 | 1.21±★★ 0.649 0.22±★ 0.262 0.20± 0.193 | 1.36±★★ 0.823 0.21±★ 0.268 0.30± 0.276 | 1.38±★★ 0.678 0.27±★ 0.328 0.33± 0.344 | 1.37±★★ 0.762 0.24±★ 0.292 0.29±★ 0.310 |
Annotate: ★ and preceding relatively P＜0.05 of treatment; ★ ★ and preceding relatively P＜0.01 of treatment.
4.3.4 the influence to other hemocyte composition: see Table 5.As seen from the table, treat and hematoblastic rising promptly occurred on the 5th day, and obvious statistical significance (P＜0.01) is arranged, hemoglobin, erythrocyte also have rising in various degree, and statistical significance (P＜0.05 or P＜0.01) is arranged.
Table 5 is to the influence of other hemocyte composition.
| Before the treatment | The 5th day | The 10th day | The 15th day | Control the 1st week of back | The 2nd week | |
| RBC number (g/L) hemoglobin (* 1012/L) platelet count (* 109/L) | 3.93± 0.692 114.6± 22.50 148.7± 69.88 | 4.22±★ 0.588 116.7± 17.09 174.4±★★ 66.73 | 4.07± 0.656 1157± 21.10 179.2±★★ 69.90 | 4.34±★★ 0.615 22.0± 17.40 191.0±★ 60.22 | 4.39±★★ 0.571 123.4★ 19.20 176.3±★★ 54.92 | 4.39±★★ 0.501 123.5±★ 16.44 193.43±★★ 50.35 |
Annotate: ★ and preceding relatively P＜0.05 of treatment; ★ ★ and preceding relatively P＜0.01 of treatment.
4.3.5 the influence to safety indexes: see Table 6.As seen from the table, rising white granule is safe in clinical practice, finds no the darling renal function infringement.
The influence of table 6 pair renal function, liver function, electrocardiogram and excrement, routine urinalysis.
| Total routine number | The unusual routine number of serum creatinine | The unusual routine number of blood urea nitrogen | The unusual routine number of ALT | Electrocardiographic abnormality example number | The unusual routine number of stool routine | The unusual routine number of routine urinalysis | |
| After treating before the treatment | 37 37 | 4 4 | 3 2 | 5 5 | 4 4 | 0 0 | 2 2 |
4.3.6 analysis of adverse reactions: in 37 routine patients of all observations, obvious adverse reaction appears in none example.
5. conclusion:
Rise the clinical efficacy of white granule therapy leukopenia: cure rate 94.6%, obvious effective rate 100%, total effective rate reaches 100%.From observed result, to take medicine and can obtain better curative effect in 5 days, leukocyte had obvious rising, promptly returned to normal level substantially to the 10th day.Rising white granule all has certain influence to the various compositions of leukocyte, but mainly is rising neutrophilic granulocyte and lymphocyte.Rising white granule also has certain influence to other hemocyte, mainly is platelet wherein, and platelet and erythrocyte, hemoglobin are also had certain rising effect.
Rise the white granule therapy QI and blood deficiency curative effect of stomach-QI being unable to descend normally card of holding concurrently: basic cure rate is 37.8%, obvious effective rate 54.1%, total effective rate 89.2%.Its cure rate, obvious effective rate are not as good as leukopenia, and be relevant with protopathy.From observed result, the syndrome integration has obvious reduction after taking medicine 9 days, with comparing difference before the treatment significance meaning (P＜0.01) is arranged.The hold concurrently syndrome integration of stomach-QI being unable to descend normally card and QI and blood deficiency and stomach-QI being unable to descend normally card of QI and blood deficiency all is synchronous downward trend.
From observed result, do not find any darling renal function infringement and other toxicity.
Above result shows, rise white granule to chemicotherapy after the leukopenia QI and blood deficiency stomach-QI being unable to descend normally card of holding concurrently obvious therapeutic action is arranged, and do not have toxicity, liked by patient.
Embodiment
1, prescription
Radix Astragali 660g Caulis Bambusae In Taenia 220g
Caulis Spatholobi 660g Folium Pyrrosiae 660g
Herba Agrimoniae 660g Fructus Crataegi 220g
Pericarpium Citri Reticulatae 220g Fructus Jujubae 220g
Ganoderma 660g pregelatinized Starch 220g
Rhizoma Pinelliae Preparata 220g lactose 110g
Ethanol, water are an amount of
It makes finished product 1000g
Method for making
(1) medical material pretreatment and batching: square Chinese crude drug is with reference to " national Chinese medicine processing standard " and " the Hunan Province's Chinese crude drug concocted specification " processing that follows an example to do, and accurately takes by weighing spice by writing out a prescription then and checks.
(2) distillating extracting oil: Pericarpium Citri Reticulatae adds 6 times of water gagings (pressing medical material weight calculates) distillation 5 hours, collects volatile oil 0.6g, and with 8 times of amount β-CDBao Hes, the enclose temperature is 50 ℃, and the enclose time is 3 hours, and it is standby to get β-CDBao He.Medicinal residues and all the other medical materials merge.
(3) boil and carry: the Radix Astragali, Caulis Spatholobi, Herba Agrimoniae, Ganoderma, Rhizoma Pinelliae Preparata, Caulis Bambusae In Taenia, Folium Pyrrosiae, Fructus Crataegi, Fructus Jujubae were soaked 0.5 hour, decoct with water secondary, add for the first time 12 times of water gagings, decocted 2 hours, merge for the second time, add 10 times of water gagings, decocted 1.5 hours with the medicinal residues that extract behind the volatile oil, filter, the extracting solution of filtrate and volatile matter distillation oil merges.
(4) concentrate: amalgamation liquid is evaporated to the clear paste that relative density is about 1.10 (60 ℃ of surveys),, send next procedure to use through after the assay was approved.
(5) system soft material: clear paste after will concentrating adds the 60g pregelatinized Starch, carries out spray drying under inlet temperature, outlet temperature 80-90 ℃, the about 730g of dry powder, adding pregelatinized Starch 160g, lactose 110g, mixing, 95% ethanol system soft material.
(6) granulate: the soft material that makes is crossed 12-14 mesh sieve system wet granular, and 60-80 ℃ of cold drying adds the about 5g of beta-CD inclusion.Granulate, altogether the about 1000g of finished product.
(7) granule that is up to the standards is packed, got product.
Claims (4)
1, a kind of Chinese medicine for the treatment of leukopenia is characterized in that the Chinese medicine that it is made by weight ratio with following Chinese medicine:
Radix Astragali 660-700 part
Caulis Spatholobi 660-700 part
Herba Agrimoniae 660-700 part
Pericarpium Citri Reticulatae 220-250 part
Ganoderma 660-700 part
Rhizoma Pinelliae Preparatum 220-250 part
Caulis Bambusae In Taenia 220-250 part
Folium Pyrrosiae 660-700 part
Fructus Crataegi 220-250 part
Fructus Jujubae 220-250 part.
2,, it is characterized in that the weight ratio of described each Chinese medicine component is according to the described Chinese medicine of claim 1:
The Radix Astragali 660
Caulis Spatholobi 660
Herba Agrimoniae 660
Pericarpium Citri Reticulatae 220
Ganoderma 660
Rhizoma Pinelliae Preparata 220
Caulis Bambusae In Taenia 220
Folium Pyrrosiae 660
Fructus Crataegi 220
Fructus Jujubae 220.
3, Chinese medicine according to claim 1 is characterized in that adding beta-CD inclusion, gelling starch, lactose; Addition 1000g contains beta-CD inclusion 5g, gelling starch 220g, lactose 110g.
4, preparation method of Chinese medicine according to claim 1, its feature comprises the steps:
Get Pericarpium Citri Reticulatae and add 6 times of water gaging distillations 5 hours, get the about 0.6g of volatile oil, with 8 times of amount β-CDBao Hes, the enclose temperature is 50 ℃, and the enclose time is 3 hours, and it is standby to get β-CDBao He; The Radix Astragali, Caulis Spatholobi, Herba Agrimoniae, Ganoderma, Rhizoma Pinelliae Preparatum, Caulis Bambusae In Taenia, Folium Pyrrosiae, Fructus Crataegi, Fructus Jujubae was soaked 0.5 hour, decoct with water secondary, add for the first time 12 times of water gagings, decocted 2 hours, merge with the medicinal residues of carrying behind the oil for the second time, relative density is about 1.10 clear paste when being evaporated to 60 ℃, adds the 60g pregelatinized Starch, at inlet temperature 180-190 ℃, carry out spray drying under outlet temperature 80-90 ℃, get dry powder, add pregelatinized Starch 160g, lactose 110g, mixing, with 85% ethanol system soft material, cross 12-14 mesh sieve system wet granular, the 60-80 cold drying adds beta-CD inclusion, granulate, altogether the about 1000g of finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310110575 CN1268381C (en) | 2003-11-27 | 2003-11-27 | Leukopenia treating Chinese traditional medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310110575 CN1268381C (en) | 2003-11-27 | 2003-11-27 | Leukopenia treating Chinese traditional medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1544028A CN1544028A (en) | 2004-11-10 |
| CN1268381C true CN1268381C (en) | 2006-08-09 |
Family
ID=34335668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310110575 Expired - Fee Related CN1268381C (en) | 2003-11-27 | 2003-11-27 | Leukopenia treating Chinese traditional medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1268381C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101642533B (en) * | 2009-09-08 | 2011-04-27 | 山东大学威海分校 | Traditional Chinese medicine preparation capable of enhancing SOD activity and lowering MDA content |
| CN102755560B (en) * | 2012-08-09 | 2014-03-12 | 南京中医药大学 | Traditional Chinese medicine compound reducing chemotherapy side reaction and preparation method and application thereof |
-
2003
- 2003-11-27 CN CN 200310110575 patent/CN1268381C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1544028A (en) | 2004-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1228074C (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN101057916A (en) | Traditional Chinese medicine composition for lowering blood-lipid, and method for preparing the same | |
| CN1966067A (en) | Medicament for treating aplastic anemia | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1268381C (en) | Leukopenia treating Chinese traditional medicine | |
| CN1248721C (en) | Chinese medicine composition for treating consumptive disease and its quality control method | |
| CN1304735A (en) | Medicine for curing chronic colitis | |
| CN1973878A (en) | Medicine for treating children's stomachache and its prepn | |
| CN1261138C (en) | Medicine for increasing immunocompetence of children and its preparing process | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1977884A (en) | Medicinal composition for treating diabetes and its preparing method | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1054541C (en) | Traditional Chinese medicine for treating mastosis | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN1386511A (en) | Medicine for preventing and treating senile dementia | |
| CN1276764C (en) | Liu-Wei-Bu-Xue granule for invigorating blood contg. six herbal medicines and its prepn. method | |
| CN1593493A (en) | Therapy assisting agent and its preparation | |
| CN1073438C (en) | Medicine for external application for curing gynecopathy | |
| CN1274353C (en) | Medication for curing children's infantile malnutrition and preparation method | |
| CN1166379C (en) | Medicine for treating kidney disease and method for preparing same | |
| CN1251741C (en) | Medicine for treating anemia and preparing method | |
| CN1337252A (en) | Chinese medicine for treating chronic bronchitis | |
| CN101066291A (en) | Chinese medicine composition for transquilizing, warming Yang, benefiting Qi and nourishing heart and its prepn | |
| CN1186054C (en) | Compound kidney-tonifying and bone-strengthening mixture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Hu Hanghui Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Huaihua Zhenghao Pharmaceutical Co.,Ltd. Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060809 Termination date: 20141127 |
|
| EXPY | Termination of patent right or utility model |